Cipher Pharmaceuticals (CPH) Stock Statistics & Valuation Metrics

Cipher Pharmaceuticals has a market cap or net worth of C$428.75M. The enterprise value is C$298.25M.

Cipher Pharmaceuticals has 25,369,642 shares outstanding. The number of shares has decreased by -2.65% in one year.

Cipher Pharmaceuticals’s return on equity (ROE) is 0.22 and return on invested capital (ROIC) is 12.78%.

The current PE Ratio of Cipher Pharmaceuticals is 10.1. Cipher Pharmaceuticals’s PEG ratio is 0.08.

In the last 12 months, Cipher Pharmaceuticals had revenue of 51.33M and earned 27.81M in profits. Earnings per share was 1.09.

In the last 12 months, operating cash flow was 29.87M and capital expenditures -108.43K, giving a free cash flow of 29.76M billion.

Cipher Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Cipher Pharmaceuticals upcoming earnings date is May 7, 2026, Before Open (Confirmed).

Cipher Pharmaceuticals as a current ratio of 1.12, with Debt / Equity ratio of 0.40%

In the past 12 months, Cipher Pharmaceuticals has paid -10.34M in taxes.

Cipher Pharmaceuticals EV to EBITDA ratio is 16.52, with an EV/FCF ratio of 9.18.

Cipher Pharmaceuticals has C$7.48M in cash and marketable securities with C$504.08K in debt, giving a net cash position of C$6.98M billion.

Gross margin is 76.50%, with operating margin of 32.73%, and net profit margin of 54.17%.

The average price target for Cipher Pharmaceuticals is C$21.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy